GlassScriptPhysician profile
Eric A Romp
NPI 1225356710
$1,069.77
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $552 · 2024: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $384.42 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $271.45 | 2023-2024 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.93 | 2023-2024 | Xifaxan, Trulance |
| Genzyme Corporation | $57.12 | 2023-2024 | |
| Celgene Corporation | $57.08 | 2023-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $36.80 | 2023-2024 | Dificid |
| Qol Medical, LLC | $34.74 | 2023-2024 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $33.89 | 2023-2024 | |
| Braintree Laboratories, INC. | $32.70 | 2023-2024 | Sutab, Suflave |
| Ardelyx, INC. | $21.55 | 2023 | Ibsrela |
| Janssen Biotech, INC. | $20.00 | 2023 | Stelara |
| Lilly USA, LLC | $18.67 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $15.42 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Romp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.